Could a heart drug help kidney patients? new trial tests finerenone for membranous nephropathy

NCT ID NCT06573411

Disease control Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding finerenone to standard blood pressure medications can lower protein in the urine of people with primary membranous nephropathy, a kidney condition that can lead to kidney failure. About 116 adults will be randomly assigned to receive either finerenone plus standard care or standard care alone. The main goal is to see if protein levels drop more with the combination after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: finerenone
What this could lead to: If successful, this could offer a new way to reduce protein leakage in the urine for people with primary membranous nephropathy, potentially slowing kidney damage.
What could go wrong: This is a relatively small Phase 4 trial with 116 participants, and the main outcome is a lab measure (proteinuria) rather than long-term kidney health. The drug may not show meaningful benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (age≥18,and ≤75) with primary MN. * Administration of the maximum tolerable dose of ACEI/ARB for ≥4 weeks. * BP ≤140/90 mmHg. * Urine protein content of 1.0-5.0 g/d. * eGFR ≥60 (CKD-EPI). * Postmenopausal or postoperatively infertile status or on medical contraception (considering the potential risk of thromboembolism in patients with kidney disease) in women. * Voluntary signing of informed consent. Exclusion Criteria: * Type 1 or type 2 diabetes. Patients with a recent history of steroid-induced diabetes were eligible with renal biopsy showing no evidence of secondary diabetic nephropathy within 6 months before the screening period. * Patients with secondary membranous nephropathy (e.g., due to hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes). * Uncontrolled arterial hypertension. * Treatment with glucocorticoids, immunosuppressants and/or biological agents in the past 6 months. * Treatment with any other study drug within the last month. * Females with a positive pregnancy screening test, lactating or planning to become pregnant in the next 24 months. Female or male patients unwilling to use contraceptive methods throughout the study. * A history of mental illness. * Laboratory tests meeting the following criteria: 1. Hemoglobin levels \<80 g/L; 2. Platelet count \<80×109/L; 3. Neutrophil count \<1.0×109/L; 4. Aspartate aminotransferase (AST) or amino aminotransferase (ALT) \>2.5 times the upper limit of normal, except in relation to the primary disease. * Very high-risk cases (life-threatening nephrotic syndrome or unexplained rapid deterioration of renal function). * Unsuitability for inclusion in the trial as judged by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Could a heart drug help kidney patients? new trial tests finerenone for membranous nephropathy

What the study statuses mean